<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127486</url>
  </required_header>
  <id_info>
    <org_study_id>18256</org_study_id>
    <secondary_id>I5Q-MC-CGBD</secondary_id>
    <nct_id>NCT05127486</nct_id>
  </id_info>
  <brief_title>A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine</brief_title>
  <acronym>CHALLENGE-MIG</acronym>
  <official_title>A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the&#xD;
      prevention of migraine in participants with episodic migraine. The study duration will be&#xD;
      approximately 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Monthly Percentage of Participants with a 50% Response Rate</measure>
    <time_frame>Month 1 through Month 3</time_frame>
    <description>The mean monthly percentage of participants will be an average of month 1 through month 3 response percentages where response is defined with ≥50% reduction from baseline in monthly migraine headache days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 3</time_frame>
    <description>Overall mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Percentage of Participants with a 75% Response Rate</measure>
    <time_frame>Month 1 through Month 3</time_frame>
    <description>The mean monthly percentage of participants will be an average of month 1 through month 3 response percentages where response is defined with ≥75% reduction from baseline in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 1 Month</time_frame>
    <description>Mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 2 Months</time_frame>
    <description>Mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</measure>
    <time_frame>Baseline, Month 1 through Month 3</time_frame>
    <description>Overall mean change from baseline in the number of monthly migraine headache days requiring medication for the acute treatment of migraine or headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Role Function-Restrictive (RF-R) Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the Role Function-Restrictive (RF-R) domain score of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Percentage of Participants with a 100% Response Rate</measure>
    <time_frame>Month 1 through Month 3</time_frame>
    <description>The mean monthly percentage of participants will be an average of month 1 through month 3 response percentages where response is defined with 100% reduction from baseline in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in MSQ v2.1 total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Role Function-Preventive (RF-P) Domain Score of Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in RF-P Domain Score of MSQ v2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Emotional Function (EF) Domain Score of Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in EF domain score of MSQ v2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MIDAS (Migraine Disability Assessment) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in MIDAS total score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Migraine</condition>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered subcutaneously (SC).&#xD;
Placebo for rimegepant will be used for blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rimegepant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rimegepant administered oral disintegrating tablets (ODT).&#xD;
Placebo for galcanezumab will be used for blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered ODT</description>
    <arm_group_label>Galcanezumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimegepant</intervention_name>
    <description>Administered ODT</description>
    <arm_group_label>Rimegepant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Rimegepant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of migraine, with or without aura, as determined by the study&#xD;
             investigator and in consideration of International Headache Society International&#xD;
             Classification of Headache Disorders - 3rd edition guidelines (ICHD-3 2018)&#xD;
&#xD;
          -  Have a history of 4 to 14 migraine headache days and at least 2 migraine attacks per&#xD;
             month on average within the past 3 months.&#xD;
&#xD;
          -  During the prospective baseline period, have a frequency of 4 to 14 migraine headache&#xD;
             days and at least 2 migraine attacks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known hypersensitivity to rimegepant or galcanezumab, and their excipients, or&#xD;
             to multiple drugs, monoclonal antibodies or other therapeutic proteins&#xD;
&#xD;
          -  Have acute cardiovascular events and/or serious cardiovascular risk, or have had&#xD;
             myocardial infarction, unstable angina, percutaneous coronary intervention, coronary&#xD;
             artery bypass graft, or stroke within 6 months of screening, or have planned&#xD;
             cardiovascular surgery or percutaneous coronary angioplasty.&#xD;
&#xD;
          -  Evidence of significant active or unstable psychiatric disease by medical history,&#xD;
             such as bipolar disorder, schizophrenia, personality disorders, or other serious mood&#xD;
             or anxiety disorders.&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Participants currently on monoclonal antibodies (mAb) calcitonin gene-related peptide&#xD;
             (CGRP) antagonists or have prior exposure to a mAb CGRP antagonist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

